FDA’s Patent And Exclusivity Team Aims To Ensure Timely First Generics
This article was originally published in The Pink Sheet Daily
Generic drugs office will proactively seek litigation and other information that could affect launch timing.
You may also be interested in...
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.